Changeflow GovPing Healthcare & Life Sciences Dana-Farber HDAC Degrader Patent, Apr 15
Routine Rule Added Final

Dana-Farber HDAC Degrader Patent, Apr 15

Favicon for changeflow.com EPO Patent Bulletin - Organic Chemistry (C07D)
Published
Detected
Email

Summary

The EPO published patent application EP4333842A1 for Class IIA Histone Deacetylase (HDAC) Degrader Ligands filed by Dana-Farber Cancer Institute, Inc., with inventors Fischer, Eric S., Xiong, Yuan, and Donovan, Katherine. The application covers compounds classified under A61K 47/55, C07D 413/14, C07D 401/04, and C07D 401/14, with designated states spanning all 31 EPC contracting states including DE, FR, GB, IT, NL, ES, PL, and SE. The therapeutic applications indicated include oncology (A61P 35/04) and neurological disorders (A61P 25/28), with compounds based on five-membered heterocyclic structures (A61K 31/4245).

Published by EPO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

About this source

GovPing monitors EPO Patent Bulletin - Organic Chemistry (C07D) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 51 changes logged to date.

What changed

The EPO published patent application EP4333842A1 establishing a priority date for Class IIA Histone Deacetylase (HDAC) Degrader Ligands and associated methods of use. The application designates all 31 EPC contracting states and covers specific therapeutic applications in oncology and neurological disorders.

Pharmaceutical and biotech companies developing targeted protein degradation therapies, particularly HDAC-based oncology candidates, should monitor this application's prosecution. The designated states include major European pharmaceutical markets (DE, FR, GB, IT, ES), and the therapeutic classifications suggest potential competition in cancer and neurodegenerative disease treatment pipelines.

Archived snapshot

Apr 25, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← EPO Patent Bulletin

CLASS IIA HISTONE DEACETYLASE (HDAC) DEGRADER LIGANDS AND METHODS OF USE THEREOF

Publication EP4333842A1 Kind: A1 Apr 15, 2026

Applicants

Dana-Farber Cancer Institute, Inc.

Inventors

FISCHER, Eric S., XIONG, Yuan, DONOVAN, Katherine

IPC Classifications

A61K 47/55 20170101AFI20260311BHEP A61P 35/04 20060101ALI20260311BHEP A61P 25/28 20060101ALI20260311BHEP A61K 31/4245 20060101ALI20260311BHEP C07D 413/14 20060101ALI20260311BHEP C07D 401/04 20060101ALI20260311BHEP C07D 401/14 20060101ALI20260311BHEP

Designated States

AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

View original document →

Get daily alerts for EPO Patent Bulletin - Organic Chemistry (C07D)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from EPO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
EPO
Published
April 15th, 2026
Instrument
Rule
Branch
International
Legal weight
Binding
Stage
Final
Change scope
Substantive

Who this affects

Applies to
Pharmaceutical companies Healthcare providers Legal professionals
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Patent application Targeted protein degradation Drug discovery
Geographic scope
European Union EU

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Pharmaceuticals Healthcare

Get alerts for this source

We'll email you when EPO Patent Bulletin - Organic Chemistry (C07D) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!